SMARCA4 and neoplasm: This also raises the possibility to avoid the loss of SMARCA2 in SCCOHT using inhibitors of ATPase/Bromodomain, since the cell line survival is dependent on the SMARCA2 loss in a SMARCA4-deficient tumor.